The efficacy of add-on treatment with phenotropil in adult patients with locally-induced epilepsy
Randomized study in people · 2014
- What was studied
- 90 adults with resistant focal epilepsy; three groups of 30, adjunctive to unchanged antiepileptic therapy
- Main finding
- The paper reports at least 50% seizure reduction in 83% and 61% of the two active groups, alongside 32 discontinuations due to adverse events.
At least 50% seizure-frequency reduction · 83% at 200 mg/day; 61% at 100 mg/day · Published results narrative; placebo responder percentage is not supplied in the checked passage · End of treatment
Reported findings and study design
The paper reports at least 50% seizure reduction in 83% and 61% of the two active groups, alongside 32 discontinuations due to adverse events.
90 adults with resistant focal epilepsy; 30 each assigned to adjunctive 200 mg/day, 100 mg/day or placebo for three months; background antiepileptic therapy unchanged.
Population or model 90 adults with resistant focal epilepsy; three groups of 30, adjunctive to unchanged antiepileptic therapy
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| At least 50% seizure-frequency reduction | 83% at 200 mg/day; 61% at 100 mg/day | Published results narrative; placebo responder percentage is not supplied in the checked passage · End of treatment |
| Adverse-event discontinuations | 12/30 at 200 mg/day; 12/30 at 100 mg/day; 8/30 with placebo | Counts as reported in methods; 32/90 total withdrawals · During three-month treatment |
| Cognitive and mood outcomes | Improvements reported; exact scale differences are in image tables | MMSE, depression, asthenia and P300 assessments; no reconstructed numbers |
| Withdrawal-associated EEG finding | 62.5% of withdrawals versus 18.8% of continuers had hypersynchronous EEG patterns | Association across treatment groups · Correlation r=0.43; p<0.05 |
The text separately describes 48 active-group completers, which does not reconcile with 60 active allocations minus 24 withdrawals. Preserve reported response percentages without reconstructing their denominators or claiming a clear intention-to-treat effect. Table images and missing-data analysis remain review priorities.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- The text separately describes 48 active-group completers, which does not reconcile with 60 active allocations minus 24 withdrawals. Preserve reported response percentages without reconstructing their denominators or claiming a clear intention-to-treat effect. Table images and missing-data analysis remain review priorities.
- Adjunctive epilepsy findings do not establish effectiveness or safety in healthy users.
Source details
Publisher HTML article
Publisher full-text results narrative and available tables checked on 1 November 2026
Sources checked
Citation
O. V. Grebeniuk, N. G. Zhukova, V. M. Alifirova. The efficacy of add-on treatment with phenotropil in adult patients with locally-induced epilepsy Zh Nevrol Psikhiatr Im S S Korsakova. 114(11 Pt 2):27–31
Study source ↗ · DOI 10.17116/jnevro201411411227-31 · Bibliography entry · Link to this summary